BACKGROUND: Real-world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited.

METHODS: We evaluated outcomes of patients with newly-diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95).

RESULTS: We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE-A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination.

CONCLUSION: HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously.

CLINICAL TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.